Owen Hughes - 14 Sep 2021 Form 4 Insider Report for Translate Bio, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 14 Sep 2021
Net transaction value: -$1,134,680
SEC form: 4
Accepted by SEC: 14 Sep 2021, 19:26:06 UTC
Prior SEC filing: 16 Jun 2021
Next SEC filing: 30 Dec 2021
Source filing: View source filing
Reporting owner signature: /s/ Paul D. Burgess, as attorney-in-fact for Owen Hughes

Key filing fact

Owen Hughes filed Form 4 for Translate Bio, Inc. on 14 Sep 2021.

Key facts

This page summarizes Owen Hughes's Form 4 filing for Translate Bio, Inc..
5 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 14 Sep 2021, 19:26.

Change

Previous filing in this sequence was filed on 16 Jun 2021.
Current net transaction value: -$1,134,680.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TBIO transaction

Common Stock

Sale

Transaction value: $1,134,680
Shares: -29,860
Change %: -100%
Price: $38.00^*
Shares after: 0
Date: 14 Sep 2021
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TBIO transaction Derivative

Stock Option (right to buy)

Sale

Transaction value: $0
Shares: -38,135
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,135
Exercise price: $7.39
Footnotes: F2, F3

TBIO transaction Derivative

Stock Option (right to buy)

Sale

Transaction value: $0
Shares: -18,900
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,900
Exercise price: $10.20
Footnotes: F2, F4

TBIO transaction Derivative

Stock Option (right to buy)

Sale

Transaction value: $0
Shares: -18,900
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,900
Exercise price: $15.33
Footnotes: F2, F5

TBIO transaction Derivative

Stock Option (righ to buy)

Sale

Transaction value: $0
Shares: -20,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $20.43
Footnotes: F2, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.

Footnote F2

Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.

Footnote F3

The shares underlying this option became fully vested on March 9, 2021.

Footnote F4

This option was granted on June 18, 2019. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2020.

Footnote F5

This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021.

Footnote F6

This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant.